论文部分内容阅读
目的研究肠道系统疾病患者血清GLS含量及其临床意义。方法以“GLS快速测定法”测定患者GLS,部分患者同时测定血清CEA,然后分组统计分析。结果肠道癌症组GLS(859±333mg/L)显著高于良性瘤(526±87)、肠炎(515±153)和“其他”(531±87)组(P<0.001),但腹腔结核组GLS(826±300)与癌症组差异无统计学意义(P>0.05);上述5组GLS阳性率依次为76.8%、11.1%1、2.0%4、.0%和62.9%。癌症组和结核组GLS阳性率高于CEA(81.4%vs.48.8%和100%vs.0,P<0.01);另3组GLS与CEA阳性率(10.0%vs.0、8.7%vs.6.5%和0 vs.0)差异无统计学意义。结论肠癌症患者血清GLS显著增加;测定血清GLS对癌症诊断具有一定临床意义,其诊断价值优于CEA。
Objective To study the serum GLS level in patients with intestinal diseases and its clinical significance. Methods GLS was determined by the rapid GLS assay, and some patients were tested for serum CEA simultaneously. Results GLS (859 ± 333 mg / L) in the intestinal cancer group was significantly higher than that in the benign tumor (526 ± 87), enteritis (515 ± 153) and the “other” group (531 ± 87) There was no significant difference between GLS (826 ± 300) in tuberculosis group and cancer group (P> 0.05). The positive rates of GLS in the five groups were 76.8%, 11.1%, 1,2.0% 4, .0% and 62.9%, respectively. The positive rates of GLS in cancer group and tuberculosis group were higher than those in CEA group (81.4% vs.48.8% and 100% vs.0, P <0.01). The positive rates of GLS and CEA in the other three groups were 10.0% vs 8.0% % And 0 vs.0) the difference was not statistically significant. Conclusion Serum GLS in patients with colorectal cancer was significantly increased. Serum GLS was of clinical significance in the diagnosis of cancer, and its diagnostic value was better than that of CEA.